Clinical trial
Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver…
NCT00308100 · Fresenius Kabi, Industry · Terminated
Key facts
| NCT number | NCT00308100 |
|---|---|
| Title | Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation |
| Official title | A Multicenter, Randomized, Open-Label, Parallel-Group, Albumin-Controlled Phase IV Study to Evaluate the Efficacy and Safety of Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Patients Undergoing Liver Transplantation |
| Lead sponsor | Fresenius Kabi, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Intraoperative Complications |
| Intervention type | Drug |
| Interventions | Hydroxyethylstarch 130/0.4, 5% Albumin |
| Enrollment | 53 |
| Start date | Oct 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Mar 29, 2006 |
| Last update posted | Jan 15, 2009 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: